To investigate the anti-PfEMP1-IgG antibody reactivity against ICAM-1-binding DBLβ domains, 137 Beninese children (median age 36 months; IQR 22 to 48 months) were recruited at three different hospital centers and divided into three clinical categories: cerebral malaria (CM), non-cerebral severe malaria (nCSM), and uncomplicated malaria (UM) (Table 1). This evidence concerns the gene ICAM1 and cerebral malaria.